Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth

Sergei I. Grivennikov, Kepeng Wang, Daniel Mucida, C. Andrew Stewart, Bernd Schnabl, Dominik Jauch, Koji Taniguchi, Guann Yi Yu, Christoph H. Österreicher, Kenneth E. Hung, Christian Datz, Ying Feng, Eric R. Fearon, Mohamed Oukka, Lino Tessarollo, Vincenzo Coppola, Felix Yarovinsky, Hilde Cheroutre, Lars Eckmann, Giorgio Trinchieri & 1 others Michael Karin

Research output: Contribution to journalArticle

547 Citations (Scopus)

Abstract

Approximately 2% of colorectal cancer is linked to pre-existing inflammation known as colitis-associated cancer, but most develops in patients without underlying inflammatory bowel disease. Colorectal cancer often follows a genetic pathway whereby loss of the adenomatous polyposis coli (APC) tumour suppressor and activation of β-catenin are followed by mutations in K-Ras, PIK3CA and TP53, as the tumour emerges and progresses. Curiously, however, 'inflammatory signature' genes characteristic of colitis-associated cancer are also upregulated in colorectal cancer. Further, like most solid tumours, colorectal cancer exhibits immune/inflammatory infiltrates, referred to as 'tumour-elicited inflammation'. Although infiltrating CD4+ T H1 cells and CD8 + cytotoxic T cells constitute a positive prognostic sign in colorectal cancer, myeloid cells and T-helper interleukin (IL)-17-producing (TH17) cells promote tumorigenesis, and a 'T H17 expression signature' in stage I/II colorectal cancer is associated with a drastic decrease in disease-free survival. Despite its pathogenic importance, the mechanisms responsible for the appearance of tumour-elicited inflammation are poorly understood. Many epithelial cancers develop proximally to microbial communities, which are physically separated from immune cells by an epithelial barrier. We investigated mechanisms responsible for tumour-elicited inflammation in a mouse model of colorectal tumorigenesis, which, like human colorectal cancer, exhibits upregulation of IL-23 and IL-17. Here we show that IL-23 signalling promotes tumour growth and progression, and development of a tumoural IL-17 response. IL-23 is mainly produced by tumour-associated myeloid cells that are likely to be activated by microbial products, which penetrate the tumours but not adjacent tissue. Both early and late colorectal neoplasms exhibit defective expression of several barrier proteins. We propose that barrier deterioration induced by colorectal-cancer- initiating genetic lesions results in adenoma invasion by microbial products that trigger tumour-elicited inflammation, which in turn drives tumour growth.

Original languageEnglish (US)
Pages (from-to)254-258
Number of pages5
JournalNature
Volume491
Issue number7423
DOIs
StatePublished - Nov 8 2012

Fingerprint

Interleukin-23
Interleukin-17
Adenoma
Colorectal Neoplasms
Growth
Neoplasms
Inflammation
Myeloid Cells
Colitis
Carcinogenesis
Th17 Cells
Catenins
Adenomatous Polyposis Coli
Growth and Development
Inflammatory Bowel Diseases

ASJC Scopus subject areas

  • General

Cite this

Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., ... Karin, M. (2012). Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature, 491(7423), 254-258. https://doi.org/10.1038/nature11465

Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. / Grivennikov, Sergei I.; Wang, Kepeng; Mucida, Daniel; Stewart, C. Andrew; Schnabl, Bernd; Jauch, Dominik; Taniguchi, Koji; Yu, Guann Yi; Österreicher, Christoph H.; Hung, Kenneth E.; Datz, Christian; Feng, Ying; Fearon, Eric R.; Oukka, Mohamed; Tessarollo, Lino; Coppola, Vincenzo; Yarovinsky, Felix; Cheroutre, Hilde; Eckmann, Lars; Trinchieri, Giorgio; Karin, Michael.

In: Nature, Vol. 491, No. 7423, 08.11.2012, p. 254-258.

Research output: Contribution to journalArticle

Grivennikov, SI, Wang, K, Mucida, D, Stewart, CA, Schnabl, B, Jauch, D, Taniguchi, K, Yu, GY, Österreicher, CH, Hung, KE, Datz, C, Feng, Y, Fearon, ER, Oukka, M, Tessarollo, L, Coppola, V, Yarovinsky, F, Cheroutre, H, Eckmann, L, Trinchieri, G & Karin, M 2012, 'Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth', Nature, vol. 491, no. 7423, pp. 254-258. https://doi.org/10.1038/nature11465
Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012 Nov 8;491(7423):254-258. https://doi.org/10.1038/nature11465
Grivennikov, Sergei I. ; Wang, Kepeng ; Mucida, Daniel ; Stewart, C. Andrew ; Schnabl, Bernd ; Jauch, Dominik ; Taniguchi, Koji ; Yu, Guann Yi ; Österreicher, Christoph H. ; Hung, Kenneth E. ; Datz, Christian ; Feng, Ying ; Fearon, Eric R. ; Oukka, Mohamed ; Tessarollo, Lino ; Coppola, Vincenzo ; Yarovinsky, Felix ; Cheroutre, Hilde ; Eckmann, Lars ; Trinchieri, Giorgio ; Karin, Michael. / Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. In: Nature. 2012 ; Vol. 491, No. 7423. pp. 254-258.
@article{30c2df29f0254f71b85855326920b08b,
title = "Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth",
abstract = "Approximately 2{\%} of colorectal cancer is linked to pre-existing inflammation known as colitis-associated cancer, but most develops in patients without underlying inflammatory bowel disease. Colorectal cancer often follows a genetic pathway whereby loss of the adenomatous polyposis coli (APC) tumour suppressor and activation of β-catenin are followed by mutations in K-Ras, PIK3CA and TP53, as the tumour emerges and progresses. Curiously, however, 'inflammatory signature' genes characteristic of colitis-associated cancer are also upregulated in colorectal cancer. Further, like most solid tumours, colorectal cancer exhibits immune/inflammatory infiltrates, referred to as 'tumour-elicited inflammation'. Although infiltrating CD4+ T H1 cells and CD8 + cytotoxic T cells constitute a positive prognostic sign in colorectal cancer, myeloid cells and T-helper interleukin (IL)-17-producing (TH17) cells promote tumorigenesis, and a 'T H17 expression signature' in stage I/II colorectal cancer is associated with a drastic decrease in disease-free survival. Despite its pathogenic importance, the mechanisms responsible for the appearance of tumour-elicited inflammation are poorly understood. Many epithelial cancers develop proximally to microbial communities, which are physically separated from immune cells by an epithelial barrier. We investigated mechanisms responsible for tumour-elicited inflammation in a mouse model of colorectal tumorigenesis, which, like human colorectal cancer, exhibits upregulation of IL-23 and IL-17. Here we show that IL-23 signalling promotes tumour growth and progression, and development of a tumoural IL-17 response. IL-23 is mainly produced by tumour-associated myeloid cells that are likely to be activated by microbial products, which penetrate the tumours but not adjacent tissue. Both early and late colorectal neoplasms exhibit defective expression of several barrier proteins. We propose that barrier deterioration induced by colorectal-cancer- initiating genetic lesions results in adenoma invasion by microbial products that trigger tumour-elicited inflammation, which in turn drives tumour growth.",
author = "Grivennikov, {Sergei I.} and Kepeng Wang and Daniel Mucida and Stewart, {C. Andrew} and Bernd Schnabl and Dominik Jauch and Koji Taniguchi and Yu, {Guann Yi} and {\"O}sterreicher, {Christoph H.} and Hung, {Kenneth E.} and Christian Datz and Ying Feng and Fearon, {Eric R.} and Mohamed Oukka and Lino Tessarollo and Vincenzo Coppola and Felix Yarovinsky and Hilde Cheroutre and Lars Eckmann and Giorgio Trinchieri and Michael Karin",
year = "2012",
month = "11",
day = "8",
doi = "10.1038/nature11465",
language = "English (US)",
volume = "491",
pages = "254--258",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7423",

}

TY - JOUR

T1 - Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth

AU - Grivennikov, Sergei I.

AU - Wang, Kepeng

AU - Mucida, Daniel

AU - Stewart, C. Andrew

AU - Schnabl, Bernd

AU - Jauch, Dominik

AU - Taniguchi, Koji

AU - Yu, Guann Yi

AU - Österreicher, Christoph H.

AU - Hung, Kenneth E.

AU - Datz, Christian

AU - Feng, Ying

AU - Fearon, Eric R.

AU - Oukka, Mohamed

AU - Tessarollo, Lino

AU - Coppola, Vincenzo

AU - Yarovinsky, Felix

AU - Cheroutre, Hilde

AU - Eckmann, Lars

AU - Trinchieri, Giorgio

AU - Karin, Michael

PY - 2012/11/8

Y1 - 2012/11/8

N2 - Approximately 2% of colorectal cancer is linked to pre-existing inflammation known as colitis-associated cancer, but most develops in patients without underlying inflammatory bowel disease. Colorectal cancer often follows a genetic pathway whereby loss of the adenomatous polyposis coli (APC) tumour suppressor and activation of β-catenin are followed by mutations in K-Ras, PIK3CA and TP53, as the tumour emerges and progresses. Curiously, however, 'inflammatory signature' genes characteristic of colitis-associated cancer are also upregulated in colorectal cancer. Further, like most solid tumours, colorectal cancer exhibits immune/inflammatory infiltrates, referred to as 'tumour-elicited inflammation'. Although infiltrating CD4+ T H1 cells and CD8 + cytotoxic T cells constitute a positive prognostic sign in colorectal cancer, myeloid cells and T-helper interleukin (IL)-17-producing (TH17) cells promote tumorigenesis, and a 'T H17 expression signature' in stage I/II colorectal cancer is associated with a drastic decrease in disease-free survival. Despite its pathogenic importance, the mechanisms responsible for the appearance of tumour-elicited inflammation are poorly understood. Many epithelial cancers develop proximally to microbial communities, which are physically separated from immune cells by an epithelial barrier. We investigated mechanisms responsible for tumour-elicited inflammation in a mouse model of colorectal tumorigenesis, which, like human colorectal cancer, exhibits upregulation of IL-23 and IL-17. Here we show that IL-23 signalling promotes tumour growth and progression, and development of a tumoural IL-17 response. IL-23 is mainly produced by tumour-associated myeloid cells that are likely to be activated by microbial products, which penetrate the tumours but not adjacent tissue. Both early and late colorectal neoplasms exhibit defective expression of several barrier proteins. We propose that barrier deterioration induced by colorectal-cancer- initiating genetic lesions results in adenoma invasion by microbial products that trigger tumour-elicited inflammation, which in turn drives tumour growth.

AB - Approximately 2% of colorectal cancer is linked to pre-existing inflammation known as colitis-associated cancer, but most develops in patients without underlying inflammatory bowel disease. Colorectal cancer often follows a genetic pathway whereby loss of the adenomatous polyposis coli (APC) tumour suppressor and activation of β-catenin are followed by mutations in K-Ras, PIK3CA and TP53, as the tumour emerges and progresses. Curiously, however, 'inflammatory signature' genes characteristic of colitis-associated cancer are also upregulated in colorectal cancer. Further, like most solid tumours, colorectal cancer exhibits immune/inflammatory infiltrates, referred to as 'tumour-elicited inflammation'. Although infiltrating CD4+ T H1 cells and CD8 + cytotoxic T cells constitute a positive prognostic sign in colorectal cancer, myeloid cells and T-helper interleukin (IL)-17-producing (TH17) cells promote tumorigenesis, and a 'T H17 expression signature' in stage I/II colorectal cancer is associated with a drastic decrease in disease-free survival. Despite its pathogenic importance, the mechanisms responsible for the appearance of tumour-elicited inflammation are poorly understood. Many epithelial cancers develop proximally to microbial communities, which are physically separated from immune cells by an epithelial barrier. We investigated mechanisms responsible for tumour-elicited inflammation in a mouse model of colorectal tumorigenesis, which, like human colorectal cancer, exhibits upregulation of IL-23 and IL-17. Here we show that IL-23 signalling promotes tumour growth and progression, and development of a tumoural IL-17 response. IL-23 is mainly produced by tumour-associated myeloid cells that are likely to be activated by microbial products, which penetrate the tumours but not adjacent tissue. Both early and late colorectal neoplasms exhibit defective expression of several barrier proteins. We propose that barrier deterioration induced by colorectal-cancer- initiating genetic lesions results in adenoma invasion by microbial products that trigger tumour-elicited inflammation, which in turn drives tumour growth.

UR - http://www.scopus.com/inward/record.url?scp=84868613705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868613705&partnerID=8YFLogxK

U2 - 10.1038/nature11465

DO - 10.1038/nature11465

M3 - Article

VL - 491

SP - 254

EP - 258

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7423

ER -